| Milagros Enriquez Capiral, PHARMACIST | |
|
79 Middleville Rd, Northport, NY 11768-2200 | |
| (631) 261-4400 | |
| Not Available |
| Full Name | Milagros Enriquez Capiral |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 79 Middleville Rd, Northport, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124127840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 031194 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Milagros Enriquez Capiral, PHARMACIST 7 Plainview Rd, Farmingdale, NY 11735-2112 Ph: (631) 261-4400 | Milagros Enriquez Capiral, PHARMACIST 79 Middleville Rd, Northport, NY 11768-2200 Ph: (631) 261-4400 |
News Archive
The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
A recent study, appearing as a preprint on the medRxiv* server, reveals the possibility of early prediction of SARS-CoV-2 infection using data on the resting heart rate in the presymptomatic period.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 7 days ago
Mr. Joseph Lawrence Magliulo, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 79 Middleville Rd, Northport, NY 11768 Phone: 631-261-4400 | |
Katherine Vicinanza, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 79 Middleville Rd, Northport, NY 11768 Phone: 631-261-4400 | |
Dr. Jennifer Angelopoulos, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 79 Middleville Rd, Northport, NY 11768 Phone: 631-261-4400 | |
Dr. Kimberly Anne Weerasinghe, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 820 Fort Salonga Rd, Northport, NY 11768 Phone: 631-261-1057 | |
Dr. Elena Abramova, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 79 Middleville Rd, Northport, NY 11768 Phone: 631-261-4400 | |
Thomas Edward Weiss, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 76 Middleville Road, Northport, NY 11768 Phone: 631-261-4400 | |
Dr. Cesar Arnold Lau-cam, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 79 Middleville Rd, Pharmacy (119), Northport, NY 11768 Phone: 631-261-4400 |